Novartis Completes Acquisition of Regulus Therapeutics
Deal News | Jun 27, 2025 | EIN
Novartis has completed its acquisition of Regulus Therapeutics Inc., incorporating the company as an indirect wholly owned subsidiary. This move aligns with Novartis' strategic focus on advancing treatments for renal diseases. The acquisition introduces a promising investigational therapy for autosomal dominant polycystic kidney disease (ADPKD) into the Novartis pipeline. Farabursen, an oligonucleotide therapy, targets miR-17 to slow cyst growth in the kidneys. Novartis has expressed optimism about integrating Regulus' team and assets to enhance its nephrology initiatives. The acquisition was finalized through a tender offer of $7.00 per share plus an additional contingent value right, following positive Phase 1b trial results for farabursen reported by Regulus.
Sectors
- Biotechnology
- Pharmaceuticals
- Healthcare
Geography
- United States – The acquisition takes place under Delaware law, and Regulus Therapeutics is a U.S.-based company.
- Switzerland – Novartis, the acquiring company, is headquartered in Switzerland, making it a relevant geography for the transaction.
Industry
- Biotechnology – The biotechnology industry is relevant as it involves the acquisition of Regulus Therapeutics, a biopharmaceutical company focused on developing therapies for genetic diseases.
- Pharmaceuticals – The pharmaceuticals industry is relevant due to Novartis' role in developing treatments for renal diseases as part of its therapeutic advancements in the healthcare sector.
- Healthcare – The healthcare industry is the overarching sector where treatments for conditions like ADPKD are developed, highlighting Novartis' commitment to improving patient outcomes.
Financials
- $7.00 per share in cash plus $7.00 CVR – The financial terms of the tender offer made by Novartis for Regulus, inclusive of cash and contingent value rights.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Novartis | Acquiring Company | Company | A Swiss multinational pharmaceutical company focusing on innovative treatments in various disease areas. |
| Regulus Therapeutics Inc. | Target Company | Company | A biopharmaceutical company engaged in developing therapies for the treatment of genetic diseases, particularly in the renal space. |
| Dr. Shreeram Aradhye | Chief Medical Officer | People | President of Development and Chief Medical Officer at Novartis, involved in the acquisition narrative. |